Related Experiment Videos
Time for a change in breast cancer therapy?
1Edinburgh University, Western General Hospital, Edinburgh EH4 2XU.
Hospital Medicine (London, England : 1998)
|December 31, 2004
Abstract:
Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.